Author： Guo Jeff J. Pandey Swapnil Doyle John Bian Boyang Lis Yvonne Raisch Dennis W.
Publisher： Blackwell Publishing
ISSN： 1098-3015
Source： Value in Health, Vol.13, Iss.5, 2010-08, pp. : 657-666
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Cardiovascular Risk-Benefit Profile of Sibutramine
By Scheen A.J.
American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :
Risk–benefit effects of tocolytic therapy
By Pryde Peter G Janeczek Susan Mittendorf Robert
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :
A Risk-Benefit Assessment of Antileukotrienes in Asthma
By Smith L.J.
Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. :